Regulatory Approval Granted Portland Orthopaedics' M-COR Primary Hip, Australia

Portland Orthopaedics Limited (ASX:PLD) has today been granted by the Australian regulator, the Therapeutic Goods Administration (TGA) final approval for the use of Portland's M-COR primary hip replacement in Australia.



Following strong uptake of the M-COR implant in the US, Portland had previously received approval for the use of the M-COR implants in the Australian market and has now received approval for the full range of instrumentation required to insert the components.



The M-COR primary hip system will be Portland's second major Australian hip product and is used for primary (first time) hip replacement patients. The M-COR is modular with a distinct neck component designed for better fit and adjustability. Its uniqueness enables the surgeon to achieve an ideal fit for each individual person's anatomy.


Mr David Sekel, managing director of Portland Orthopaedics said, "This is an exciting time for Portland as are now able to market and sell two systems into the domestic market. Following the success that we have had in the US with the M-COR this will enable Portland to get a solid foundation into the Australian market."



About Portland Orthopaedics


Listed on the ASX in December 2005, Portland (ASX:PLD) is a developer and manufacturer of specialist hip replacements. Portland's first product, the DTC Hip, was conceived in 1991 as standard hip implants proved inadequate in cases with substantial bone loss especially where a hip implant had already been inserted. Portland's first hip implant was trialled in 1997 and so far more than 2,000 implants have been sold, the majority in the US and Australia.


Portland has regulatory approval to sell a range of primary, revision and tumour hip replacement products in the US, Europe, Australia, New Zealand and Israel. The core technologies are all patented and future applications include shoulders, ankles and other joints.


portland-orthopaedics